Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds.

ABSTRACT: The use of intracellular antibodies as templates to derive surrogate compounds is an important objective because intracellular antibodies can be employed initially for target validation in pre-clinical assays and subsequently employed in compound library screens. LMO2 is a T cell oncogenic protein activated in the majority of T cell acute leukaemias. We have used an inhibitory intracellular antibody fragment as a competitor in a small molecule library screen using competitive surface plasmon resonance (cSPR) to identify compounds that bind to LMO2. We selected four compounds that bind to LMO2 but not when the anti-LMO2 intracellular antibody fragment is bound to it. These findings further illustrate the value of intracellular antibodies in the initial stages of drug discovery campaigns and

SUBMITTER: Canning P 

PROVIDER: S-EPMC8208243 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature